top of page

Catching up with Roberto Bellini one year after he sold BELLUS Health to GSK for $2 billion

May 14, 2024
1 min read

Roberto Bellini introduces us to his new investment firm and looks back on lessons learned from selling BELLUS to GSK.

Recent Posts

BIO 2026: Sofinnova Investments' Managing Partner Jim Healy shares his (optimistic) take on the current state of biotech and the venture side of it

BIO 2026: Sofinnova Investments' Managing Partner Jim Healy shares his (optimistic) take on the current state of biotech and the venture side of it

EHA 2026: H.C. Wainwright Senior Biotech Analyst Mitchell Kapoor previews key EHA data from Legend and Incyte, and shares catalysts he is watching for after the conference

EHA 2026: H.C. Wainwright Senior Biotech Analyst Mitchell Kapoor previews key EHA data from Legend and Incyte, and shares catalysts he is watching for after the conference

At Nucleate UK's The Forum in London, former Novo Nordisk CSO Marcus Schindler reflects on the success of the GLPs and shares advice for biotech entrepreneurs in Europe

At Nucleate UK's The Forum in London, former Novo Nordisk CSO Marcus Schindler reflects on the success of the GLPs and shares advice for biotech entrepreneurs in Europe

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page